Please login to the form below

Not currently logged in
Email:
Password:

Cornerstone Therapeutics

This page shows the latest Cornerstone Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Chiesi hits the acquisition trail again

Chiesi hits the acquisition trail again

Chiesi hits the acquisition trail again. Will buy US speciality pharma company Cornerstone. ... Italy's Chiesi has signed its second acquisition deal in as many months, agreeing a $9.50-a-share deal for US speciality pharma company Cornerstone

Latest news

  • Cornerstone slumps as FDA panel votes down lead pipeline drug

    US pharma company Cornerstone Therapeutics suffered a setback after an FDA advisory committee voted against approval of lixivaptan, the firm's drug candidate for hyponatremia or low sodium levels in the ... It was originally developed by Wyeth and

  • Pharma deals for May 2012 Pharma deals for May 2012

    This can effectively kill a deal and potentially the product. Another example of a product acquisition is InterMune's sale of its approved product, Actimmune (interferon gamma-1b), to Vidara Therapeutics ... NCEs for respiratory disease. 212. EKR

  • Biologics buoyant

    Three of the deals, with Amplimmune, FivePrime Therapeutics and Genmab, focus on biologics. ... 84+. Cornerstone Therapeutics/Targacept . Alpha-7 and other nicotinic receptor targeting compounds. Preclinical .

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch table for September 2013 Deal Watch table for September 2013

    Cornerstone Therapeutics/ Chiesi Farmaceutici. Acquisition (42 per cent). US speciality pharmaceutical company focused hospital and niche respiratory products. ... Cornerstone Therapeutics, respectively.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics